Table 2.
Canine pediatric vaccines: core, noncore, and generally not recommended
| Canine | Core | Noncore | Not recommended |
|---|---|---|---|
| CDV | MLV or recombinant beginning at 6–9 weeks, given every 3–4 weeks until ∼16 weeks of age | ||
| CAV II | MLV, frequency as for CDV | ||
| Parvovirus | MLV, frequency as for CDV | ||
| Rabies | Killed, single dose, minimum age dependent on state and local regulations (12 or 16 weeks) | ||
| Leptospirosis | Killed bacterin or purified subunit product beginning at 12 weeks, 2 to 3 doses given at 4- week intervals | ||
| Bordetella bronchiseptica | Attenuated bacterin, a single dose of an intranasal vaccine given 1 week before potential exposure (minimum of 4 weeks of age) | ||
| Parainfluenza | MLV, either use topical product combined with B bronchiseptica or parenteral vaccine contained in multivalent DAPP products | ||
| Lyme disease (Borrelia burgdorferi) | Recombinant subunit vaccine (OspA) before exposure to ticks, 2 doses given 4 weeks apart beginning at 9 weeks of age | ||
| Measles | No longer recommended, use recombinant distemper vaccine for high-risk puppies instead of measles | ||
| Coronavirus | Not recommended | ||
| Giardia lamblia | Not recommended | ||
| Rattlesnake vaccine | Insufficient data to evaluate efficacy; prevention of exposure, aversion training, and immediate veterinary attention after exposure highly recommended | ||
| CAV I | Not recommended; CAV II to prevent CAV I infection is highly recommended |
Abbreviations: CAV, canine adenovirus; CDV, canine distemper virus; DAPP, distemper, parvovirus, and parainfluenza; MLV, modified-live virus; OspA, outer surface protein A